Streetwise Reports' Article Archives — January 2026 back to current month (7)
Clean Tech Developer Sees Massive Opportunity in PFAS Treatment (01/29/2026)
BioLargo Inc. (BLGO:OTCQX) announces that its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system has been installed in New Jersey. Find out why the company sees massive upside for its products.
Environmental Firm Finds High-Value Position in PFAS Remediation Industry (01/28/2026)
BioLargo Inc. (BLGO:OTCQX) has announced the installation of its patented Aqueous Electrostatic Concentrator (AEC) PFAS treatment system in New Jersey. Discover why the company anticipates significant potential for its products.
Report of FDA Drug Approval Delay is 'Likely Noise': Analyst (01/27/2026)
Disc Medicine Inc.'s (IRON:NASDAQ) chances of bitopertin getting approved remain unaltered by the claims in a recent article, noted an H.C. Wainwright & Co. report. Read on to learn the reasons behind this opinion of the investment bank.
Biotech Co. Expands Testing Tied to its Cell Pouch Bio-hybrid Organ (01/13/2026)
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTC; PSH:XETRA) seeks to determine how a newly developed immunosuppressive agent and, separately, how a different type of islet will work in conjunction with cell implantation via its proven Cell Pouch Bio-hybrid Organ, noted a Leede Financial Inc. report. Read on to learn more about what this Speculative Buy-rated company is working on.
Analysts Highlight Notable H1/26 Catalysts in Biotech (01/12/2026)
Despite the overall run-up in biotech names last year, the sector still offers "several attractive H1/26 catalyst set-ups, noted an RBC Capital Markets report. Find out which upcoming events the analysts like the most and the least.
AI Collaboration Expands to Accelerate Cancer Drug Discovery (01/12/2026)
Rakovina Therapeutics Inc. (RKV:TSX.V) has broadened its partnership with Variational AI to refine next-generation ATR inhibitors using generative AI. The agreement aims to streamline lead optimization for the company's kt-5000 series of small-molecule cancer drug candidates.
Expanded AI Collaboration Advances Optimization of Cancer Drug Candidates (01/09/2026)
Rakovina Therapeutics Inc. (RKV:TSX.V) has expanded its partnership with Variational AI to advance optimization of its kt-5000 ATR inhibitor series. Learn how the agreement deepens the company's use of generative AI to refine small-molecule drug candidates and accelerate preclinical selection.
More Archives
2026Jan
2025Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2024Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
